Background: Retinal vein occlusion is the second most common retinal vascular disease after diabetic retinopathy. Branch retinal venous occlusion (BRVO) occurs the occlusion of one of the branches of the retinal vein. The occlusion occurs mostly at arteriovenous crossing and more frequent in upper temporal retinal veins. Patients and Methods: In the current study, randomized control study was conducted on 2 groups divided into 27 eyes (Ranibizumab alone), 27 eyes (Ranibizumab and Targeted retinal laser). Results: The BRVO is investigated by FFA and OCT-Macula and macular edema is measured by OCT-Macula. And the current result shows highly statistically significant improvement in visual acuity and reducing macular edema (decrease foveal thickness)with P value <0.001 in Ranibizumab alone compared with Ranibizumab and retinal laser.